CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 12, 2022—BioMérieux has entered into an agreement to acquire Specific Diagnostics, a privately held, U.S.-based company that developed the Specific Reveal Rapid AST system. BioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies signed a co-distribution agreement in 2021 for the European market.
The Specific Reveal Rapid AST system provides results for Gram-negative bacteria directly from positive blood cultures in about five hours. The system offers an easy-to-use instrument with a targeted menu, small footprint, and modular design and integrates with BioMérieux’s sepsis solution, including BACT/Alert Virtuo, Vitek MS Prime, BioFire BCID2, Vidas PCT, and Vitek 2.
Pages: 1 2